Central Catecholamine Metabolism in Vivo and the Cognitive and Motor Deficits in Parkinson's Disease

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 1983 Oct 1

PMID 6644314

Citations 9

Authors

J J Mann

M Stanley

R D Kaplan

J Sweeney

A Neophytides

Affiliations

Soon will be listed here.

Abstract

Cerebrospinal fluid levels of homovanillic acid (HVA) in unmedicated patients with Parkinson's disease were 45% of levels in control subjects. Levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and platelet monoamine oxidase activity (MAO) did not differ. Within the Parkinson's disease group platelet MAO B activity correlated with HVA (an MAO B substrate) but not MHPG (an MAO A substrate). A mild global dementia was found that did not correlate with the more severe motor deficit. There was a negative correlation between the motor deficit and HVA levels but not with MHPG. Cognitive functioning correlated positively with platelet MAO, and the ratio of HVA to MHPG levels and negatively with MHPG alone. It is postulated that dopaminergic and noradrenergic activity or the functional balance between these systems may contribute to the observed cognitive dysfunction.

Citing Articles

Longitudinal sex-specific impacts of high-fat diet on dopaminergic dysregulation and behavior from periadolescence to late adulthood.

Maldonado-Devincci A, Odelade A, Irby-Shabazz A, Jadhav V, Nepal P, Chang E Nutr Neurosci. 2024; :1-14.

PMID: 39046103 PMC: 11757805. DOI: 10.1080/1028415X.2024.2377471.

High-Fat Diet-Induced Weight Gain, Behavioral Deficits, and Dopamine Changes in Young C57BL/6J Mice.

Han J, Nepal P, Odelade A, Freely F, Belton D, Graves Jr J Front Nutr. 2021; 7:591161.

PMID: 33553228 PMC: 7855171. DOI: 10.3389/fnut.2020.591161.

Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.

Butkovich L, Houser M, Chalermpalanupap T, Porter-Stransky K, Iannitelli A, Boles J J Neurosci. 2020; 40(39):7559-7576.

PMID: 32868457 PMC: 7511194. DOI: 10.1523/JNEUROSCI.1468-19.2020.

Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Jimenez-Jimenez F, Alonso-Navarro H, Garcia-Martin E, Agundez J Front Cell Neurosci. 2014; 8:369.

PMID: 25426023 PMC: 4227512. DOI: 10.3389/fncel.2014.00369.

Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.

McMillan P, White S, Franklin A, Greenup J, Leverenz J, Raskind M Brain Res. 2010; 1373:240-52.

PMID: 21147074 PMC: 3038670. DOI: 10.1016/j.brainres.2010.12.015.

References

GILBERT J, LEVEE R . Patterns of declining memory. J Gerontol. 1971; 26(1):70-5. DOI: 10.1093/geronj/26.1.70. View

Rinne U, Lonnberg P, Koskinen V . Dopamine receptors in the Parkinsonian brain. J Neural Transm. 1981; 51(1-2):97-106. DOI: 10.1007/BF01664007. View

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

Robinson D, Sourkes T, Nies A, Harris L, Spector S, Bartlett D . Monoamine metabolism in human brain. Arch Gen Psychiatry. 1977; 34(1):89-92. DOI: 10.1001/archpsyc.1977.01770130091009. View

Marttila R, Rinne U . Dementia in Parkinson's disease. Acta Neurol Scand. 1976; 54(5):431-41. DOI: 10.1111/j.1600-0404.1976.tb04375.x. View

BOWERS Jr M, Gerbode F . Relationship of monoamine metabolites in human cerebrospinal fluid to age. Nature. 1968; 219(5160):1256-7. DOI: 10.1038/2191256a0. View

VAN WOERT M, BOWERS Jr M . The effect of L-dopa on monoamine metabolites in Parkinson's disease. Experientia. 1970; 26(2):161-3. DOI: 10.1007/BF01895555. View

Kahn R, GOLDFARB A, Pollack M, Peck A . Brief objective measures for the determination of mental status in the aged. Am J Psychiatry. 1960; 117:326-8. DOI: 10.1176/ajp.117.4.326. View

Parkes J, Marsden C, Rees J, Curzon G, Kantamaneni B, Akbar A . Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa. Q J Med. 1974; 43(169):49-61. View

10.

ZELLER E, BOSHES B, ARBIT J, Bieber M, BLONSKY E, Dolkart M . Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase. J Neural Transm. 1976; 39(1-2):63-77. DOI: 10.1007/BF01248766. View

11.

Lloyd K, Hornykiewicz O . Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science. 1970; 170(3963):1212-3. DOI: 10.1126/science.170.3963.1212. View

12.

Meier M, Martin W . Intellectual changes associated with levodopa therapy. JAMA. 1970; 213(3):465-6. View

13.

LORANGER A, GOODELL H, Lee J, McDowell F . Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning. Arch Gen Psychiatry. 1972; 26(2):163-8. DOI: 10.1001/archpsyc.1972.01750200067014. View

14.

Stein L, Belluzzi J, WISE C . Memory enhancement by central administration of norepinephrine. Brain Res. 1975; 84(2):329-35. DOI: 10.1016/0006-8993(75)90989-0. View

15.

Watson E, Wilk S . Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography. Psychopharmacologia. 1975; 42(1):57-6. DOI: 10.1007/BF00428826. View

16.

Mann J, Stanley M, Neophytides A, de Leon M, Ferris S, Gershon S . Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit. Neurobiol Aging. 1981; 2(1):57-60. DOI: 10.1016/0197-4580(81)90060-9. View

17.

Shoulson I, Chase T . Clonidine and the anti-parkinsonian response to L-DOPA or piribedil. Neuropharmacology. 1976; 15(1):25-7. DOI: 10.1016/0028-3908(76)90093-9. View

18.

Riederer P, Birkmayer W, Seemann D, Wuketich S . Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J Neural Transm. 1977; 41(4):241-51. DOI: 10.1007/BF01252019. View

19.

PAPESCHI R, Sourkes T, Hardy J, Bertrand C . Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesias. Neurology. 1970; 20(10):991-5. DOI: 10.1212/wnl.20.10.991. View

20.

Donnelly E, Chase T . Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa. Dis Nerv Syst. 1973; 34(2):119-23. View